Literature DB >> 1382994

Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene.

N Motoyama1, N Okada, M Yamashina, H Okada.   

Abstract

HRF20 (CD59) is a membrane glycoprotein which protects cells from the membrane attack reaction of homologous complement. A patient who is completely deficient in HRF20 expression and is suffering from paroxysmal nocturnal hemoglobinuria (PNH) was studied. His parents are cousins and both have decreased HRF20 expression, suggesting that the deficiency is genetic. We established a cultured cell line (NCU1) which is HRF20 deficient from the patient's lymphocytes by Epstein-Barr-virus (EBV) infection. Northern blot analysis revealed HRF20 mRNA signals, indicating that HRF20 mRNA were transcribed. HRF20 cDNA was amplified by the polymerase chain reaction (PCR) method. Sequencing of the cDNA from the NCU1 showed two single-base deletions at amino acid 16 and 96 from the N terminus of the mature protein. Deletion in the genomic DNA of peripheral blood lymphocytes was confirmed by the DNA sequence of an HRF20 open reading frame containing amino acid 16. Furthermore, the patient's parents and sister possessed both intact and deleted genomic HRF20 DNA while his brother's DNA was intact. These findings demonstrate that the HRF20 deficiency was genomic in origin, and that complete deletion was brought about by a homozygous abnormality in the HRF20 gene. The base deletion caused a codon frame shift resulting in failure to produce intact HRF20 protein in the patient.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382994     DOI: 10.1002/eji.1830221029

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

Review 1.  Pathogenesis and mechanisms of antibody-mediated hemolysis.

Authors:  Willy A Flegel
Journal:  Transfusion       Date:  2015-07       Impact factor: 3.157

Review 2.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 3.  Development of complement therapeutics for inhibition of immune-mediated red cell destruction.

Authors:  Karina Yazdanbakhsh
Journal:  Transfusion       Date:  2005-08       Impact factor: 3.157

4.  Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena.

Authors:  Alexander Röth; Christina Hock; Anna Konik; Sandra Christoph; Ulrich Dührsen
Journal:  Int J Hematol       Date:  2011-05-25       Impact factor: 2.490

5.  A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patient.

Authors:  Markus Anliker; Inge von Zabern; Britta Höchsmann; Henriette Kyrieleis; Christian Dohna-Schwake; Willy A Flegel; Hubert Schrezenmeier; Christof Weinstock
Journal:  Transfusion       Date:  2014-01-03       Impact factor: 3.157

Review 6.  Heterogeneity in the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria (PNH) syndromes and expansion mechanism of a PNH clone.

Authors:  Tsutomu Shichishima; Hideyoshi Noji
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

7.  Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria.

Authors:  Anna M Jankowska; Hadrian Szpurka; Mark Calabro; Sanjay Mohan; Andrew E Schade; Michael Clemente; Roy L Silverstein; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

Review 8.  Association of Blood Group Antigen CD59 with Disease.

Authors:  Christof Weinstock
Journal:  Transfus Med Hemother       Date:  2022-01-13       Impact factor: 3.747

9.  Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.

Authors:  Jörg Schubert; Peter Hillmen; Alexander Röth; Neal S Young; Modupe O Elebute; Jeffrey Szer; Giacomo Gianfaldoni; Gérard Socié; Paul Browne; Robert Geller; Russell P Rother; Petra Muus
Journal:  Br J Haematol       Date:  2008-05-22       Impact factor: 6.998

10.  Identification of MIC 11 antigen as an epitope of the CD59 molecule.

Authors:  A Davies; A B Wilson; J C Bramley; C Willers; V Van Heyningen; W A Bickmore; P J Lachmann
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.